| Literature DB >> 29933573 |
Sara El Kennani1, Marion Crespo2, Jérôme Govin3, Delphine Pflieger4,5.
Abstract
Epigenetic modifications contribute to the determination of cell fate and differentiation. The molecular mechanisms underlying histone variants and post-translational modifications (PTMs) have been studied in the contexts of development, differentiation, and disease. Antibody-based assays have classically been used to target PTMs, but these approaches fail to reveal combinatorial patterns of modifications. In addition, some histone variants are so similar to canonical histones that antibodies have difficulty distinguishing between these isoforms. Mass spectrometry (MS) has progressively developed as a powerful technology for the study of histone variants and their PTMs. Indeed, MS analyses highlighted exquisitely complex combinations of PTMs, suggesting “crosstalk” between them, and also revealed that PTM patterns are often variant-specific. Even though the sensitivity and acquisition speed of MS instruments have considerably increased alongside the development of computational tools for the study of multiple PTMs, it remains challenging to correctly describe the landscape of histone PTMs, and in particular to confidently assign modifications to specific amino acids. Here, we provide an inventory of MS-based strategies and of the pitfalls inherent to histone PTM and variant characterization, while stressing the complex interplay between PTMs and histone sequence variations. We will particularly illustrate the roles played by MS-based analyses in identifying and quantifying histone variants and modifications.Entities:
Keywords: bottom-up analysis; computational tools; crosstalk; histone variants; mass spectrometry; post-translational modifications
Year: 2018 PMID: 29933573 PMCID: PMC6161106 DOI: 10.3390/proteomes6030029
Source DB: PubMed Journal: Proteomes ISSN: 2227-7382
Figure 1Sequence similarity between histone variants in human and mouse. Core histones H2A (yellow), H2B (red), H3 (blue), and histone linker H1 (purple) are illustrated for mouse (A) and human (B). Sequence data were obtained from and treated as published in Reference [17].
Figure 2Representation of bottom-up, middle-down, and top-down mass spectrometry experiments.
Figure 3Challenges of histone post-translational modifications (PTM) assignments. The Mass Spectrometry fragmentation (MS/MS) spectra of higher energy collisional dissociation (HCD) fragmented histone peptides are shown. Case 1 illustrates positional isomers for the di-acetylated N-terminal tail of histone H4 containing the four Lysine residues K5, K8, K12, and K16. The left spectrum illustrates the identification of the first positional isomer indicated in the diagram, with a Mascot identification score of 65. On the right, the same spectrum is interpreted with fragments of the second possible modified sequence matched with a score of 56. Fragment ions b2, y5, y7, and y9 and y12++ can be used to assign acetylation on different lysine residues. Case 2 illustrates the difficulty associated with confidently assigning a Lys36 or Lys37 di-methylation to peptide K, as it relies only on the weak-intensity y4 fragment to discriminate between these two modifiable residues. Case 3 shows the probable co-fragmentation of the co-eluting peptides K27me1-K36me2 and K27me2-K36me1. The two positional isomers are matched to this MS/MS spectrum with Mascot scores 31 and 29, respectively. Discriminating b3, b5, y8, y9 and y10 fragment ions are detectable at high intensity in the spectrum. Case 4 illustrates ambiguity between amino acid variation and combination of PTMs. The masses of peptides K18QLATK23acVAR from TS H3.4 and K18QLATK23buAAR from H3.1/H3.2 are strictly equal. A diagnostic ion at m/z 126.091 indicates the presence of an acetylated Lys residue in the fragmented peptide, and thus orients toward the identification of acetylated TS H3.4.
Figure 4Examples of isobaric PTM combinations. Differentiating structures in the Lys side chain are highlighted in yellow with an indication of their corresponding masses.
Figure 5Sequence alignment for mouse histone H3 and its variants.
Diagnostic ions useful for PTM assignment. Immonium ions (IM); side-chain fragmentations (SC); neutral losses (NL).
| Amino Acid Residues | PTMs | Diagnostic Ion Type | MS Fragmentation | References | |
|---|---|---|---|---|---|
| Lysine | Acetylation | IM-NH3 | 126.091 | CID, HCD | [ |
| Methylation | IM-NH3 | 98.0964 | CID, HCD | [ | |
| Dimethylation | IM | 112.1 | CID, HCD | [ | |
| Trimethylation | NL | 59.0735 | CID | [ | |
| Propionyl | IM | 140.106 | CID | [ | |
| Crotonyl | __ | __ | __ | __ | |
| Butyryl | IM | 154.123 | HCD | [ | |
| Malonyl | __ | __ | __ | __ | |
| 2-hydroxyisobutyryl | __ | __ | __ | __ | |
| Succinyl | __ | __ | __ | __ | |
| Gluratyl | __ | __ | __ | __ | |
| Formyl | IM | 112.0756 | HCD | [ | |
| Arginine | Methylation | NL | 73.064 | ETD | [ |
| Methylation | NL | 31.0422 | ETD | [ | |
| Dimethylation | SC | 46.0651 | CID | [ | |
| Dimethylation-symmetric/asymmetric | SC | 71.0604 | CID | [ | |
| Dimethyl-symmetric | NL | 31.0417 | CID | [ | |
| Dimethylation-symmetric | NL | 46.0651 | CID | 59,60,64] | |
| Dimethylation-asymmetric | NL | 45.0573 | CID | [ | |
| Tyrosine | phosphoryl | NL | 216.0426 | CID | [ |